The purpose of this registry project is to assess all the information received from the Agendia Breast Cancer Suite to assist in breast cancer diagnosis and treatment decisions. The Agendia Breast Cancer Suite includes MammaPrint®, TargetPrint®, BluePrint™ and TheraPrint™. MammaPrint, an FDA cleared test, is used clinically to determine your risk for distant metastasis (the spread of cancer from one part of the body to another).
Prospective Neoadjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony™ Trial (NBRST) (pronounced “in breast”)
991-11Principal Investigator: Conducted at:
Long Beach Medical CenterCurrently enrolling additional patients:
18 to 90Gender: